In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Elevance Health Inc (NYSE: ELV) closed the day trading at $312.0 up 0.87% from the previous closing price of $309.32. In other words, the price has increased by $0.87 from its previous closing price. On the day, 2.44 million shares were traded. ELV stock price reached its highest trading level at $315.99 during the session, while it also had its lowest trading level at $308.53.
Ratios:
For a better understanding of ELV, let’s look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.69 whereas as Long-Term Debt/Eq ratio is at 0.64.
On July 18, 2025, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $310.
Robert W. Baird Downgraded its Outperform to Neutral on April 15, 2025, while the target price for the stock was maintained at $529.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 18 ’25 when BOUDREAUX GAIL bought 8,500 shares for $286.94 per share. The transaction valued at 2,438,951 led to the insider holds 151,020 shares of the business.
Kaye Mark sold 4,588 shares of ELV for $1,949,074 on Apr 24 ’25. The EVP & CFO now owns 18,977 shares after completing the transaction at $424.82 per share. On Apr 24 ’25, another insider, Kaye Mark, who serves as the Officer of the company, bought 4,588 shares for $424.81 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELV now has a Market Capitalization of 70255534080 and an Enterprise Value of 65778630656. As of this moment, Elevance’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.28, and their Forward P/E ratio for the next fiscal year is 9.79. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.37 while its Price-to-Book (P/B) ratio in mrq is 1.60. Its current Enterprise Value per Revenue stands at 0.348 whereas that against EBITDA is 6.934.
Stock Price History:
The Beta on a monthly basis for ELV is 0.60, which has changed by -0.4247151 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, ELV has reached a high of $567.26, while it has fallen to a 52-week low of $273.71. The 50-Day Moving Average of the stock is -5.32%, while the 200-Day Moving Average is calculated to be -18.77%.
Shares Statistics:
Over the past 3-months, ELV traded about 2.35M shares per day on average, while over the past 10 days, ELV traded about 2349520 shares per day. A total of 224.84M shares are outstanding, with a floating share count of 224.74M. Insiders hold about 0.19% of the company’s shares, while institutions hold 92.66% stake in the company. Shares short for ELV as of 1753920000 were 2840716 with a Short Ratio of 1.21, compared to 1751241600 on 2539048. Therefore, it implies a Short% of Shares Outstanding of 2840716 and a Short% of Float of 1.26.
Dividends & Splits
ELV’s forward annual dividend rate is 6.68, up from 6.68 a year ago. Against a Trailing Annual Dividend Yield of 0.021595757The stock’s 5-year Average Dividend Yield is 1.22. The current Payout Ratio is 25.39% for ELV, which recently paid a dividend on 2025-06-10 with an ex-dividend date of 2025-09-10. Stock splits for the company last occurred on 2005-06-01 when the company split stock in a 2:1 ratio.
Earnings Estimates
The dynamic stock of Elevance Health Inc (ELV) is currently attracting attention from 16.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $4.11, with high estimates of $4.54 and low estimates of $1.96.
Analysts are recommending an EPS of between $32.15 and $28.77 for the fiscal current year, implying an average EPS of $30.02. EPS for the following year is $32.78, with 21.0 analysts recommending between $39.23 and $26.97.
Revenue Estimates
10 analysts predict $49.22B in revenue for the current quarter. It ranges from a high estimate of $50.2B to a low estimate of $48.65B. As of the current estimate, Elevance Health Inc’s year-ago sales were $44.72BFor the next quarter, 10 analysts are estimating revenue of $49.36B. There is a high estimate of $50.9B for the next quarter, whereas the lowest estimate is $47.78B.
A total of 12 analysts have provided revenue estimates for ELV’s current fiscal year. The highest revenue estimate was $199.04B, while the lowest revenue estimate was $194.96B, resulting in an average revenue estimate of $196.92B. In the same quarter a year ago, actual revenue was $175.2BBased on 10 analysts’ estimates, the company’s revenue will be $208.37B in the next fiscal year. The high estimate is $213.85B and the low estimate is $200.55B.
